Raptor Pharmaceutical Corp. (NASDAQ:RPTP), a biopharmaceutical company focused on developing and commercializing transformative treatments for people affected by rare and debilitating diseases, today announced that it has priced an underwritten public offering of 9,500,000 shares of its common stock at a price to the public of $9.00 per share. In addition, Raptor has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 1,425,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions. Gross proceeds before underwriting discounts and commissions and estimated expenses of the offering payable by the company are expected to be approximately $85.5 million, or approximately $98.3 million if the underwriters exercise their option to purchase the additional shares in full. The offering is expected to close on April 8, 2015, subject to customary closing conditions. All of the shares are being offered by the company.
Citigroup, Leerink Partners and Cowen and Company are acting as lead joint book-running managers for the offering. JMP Securities is acting as lead manager and Janney Montgomery Scott is acting as a co-manager for the offering.
A registration statement relating to these securities was filed with the Securities and Exchange Commission (SEC) and became automatically effective on March 30, 2015. This offering is being made solely by means of a prospectus supplement and accompanying prospectus. A final prospectus supplement and accompanying prospectus related to the offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov. When available, copies of the final prospectus supplement and accompanying prospectus related to the offering may also be obtained from Citigroup Global Markets Inc., Attention: c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, New York, 11717, or by phone at (800) 831-9146, or by email at firstname.lastname@example.org; or from the offices of Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, Massachusetts 02110, or by phone at (800) 808-7525, or by email at email@example.com.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor will there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or other jurisdiction.
Shares of Raptor closed yesterday at $9.98 . RPTP has a 1-year high of $12.20 and a 1-year low of $7.12. The stock's 50-day moving average is $10.62 and it's 200-day moving average is $10.02.
On the ratings front, Raptor has been the subject of a number of recent research reports. In a report issued on February 27, Wedbush analyst David Nierengarten reiterated a Sell rating on RPTP, with a price target of $5, which represents a potential downside of 49.9% from where the stock is currently trading. Separately, on February 24, Oppenheimer's Christopher Marai reiterated a Hold rating on the stock .
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, David Nierengarten and Christopher Marai have a total average return of 44.7% and 35.7% respectively. Nierengarten has a success rate of 64.0% and is ranked #19 out of 3564 analysts, while Marai has a success rate of 74.6% and is ranked #26.
Raptor Pharmaceutical Corp is abiopharmaceuticalcompany. It is engaged indeveloping and commercializing transformative treatments for people affected by rare and debilitating diseases.